Gastélum-Fernández V, Rodríguez-Montalvo C, Flores-Villalba E, Tijerina-Gómez L, Bosques-Padilla F, Carrillo M, Castilleja F

Language: Spanish
References: 15
Page: 102-106
PDF size: 314.68 Kb.

ABSTRACT

Liver transplantation is one of the definitive treatments for hepatocellular carcinoma (HCC). The criteria of Milan and UCSF are best used for eligibility of a candidate for transplant with HCC. Currently, patients who exceed the established criteria, the bridge therapy is proposed by using adjuvant therapies such as chemoembolization and transarterial tumor embolization to reduce the size of the lesion, known as down staging. We describe a patient with a single 5.8 cm tumor who received a soft embolization as down-staging therapy, and after two months received a liver transplant. After 18 months, the patient is alive without recurrence of the tumor. The usefulness of transarterial embolization as down staging therapy in a patient with hepatocellular carcinoma is demonstrated.

REFERENCES

1. Del Pozo AC, López P. Management of hepatocellular carcinoma. Clin Liver Dis. 2007; 11: 305-321.

2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013; 132: 1133-1145.

3. Llovet JM, Real MI, Montaña X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739.

4. Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008; 195: 829-836.

5. Colleoni M, Bajetta E, Nelli P et al. Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan. Ann Oncol. 1993; 4: 489-493.

6. Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transpl. 2007; 13: S44-S47.

7. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999; 229: 790-799; discussion 799-800.

8. Masuoka HC, Rosen CB. Liver transplantation for hepatocellular carcinoma: expanding frontiers and building bridges. Clin Liver Dis. 2011; 15: 385-93, VII-X.

9. Yao FY, Kerlan RK, Hirose R et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48: 819-827.

10. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011; 17 (Suppl. 2): S109-S116.

11. Ravaioli M, Grazi GL, Cescon M et al. Down-staging of hepatocellular carcinoma before liver transplantation: should we change our clinical practice? Ann Surg. 2009; 250: 348; author reply 348-9.

12. Ravaioli M, Grazi GL, Piscaglia F et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008; 8: 2547-2557.

13. El-Gazzaz G, Sourianarayanane A, Menon KV et al. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. Hepatobiliary Pancreat Dis Int. 2013; 12: 34-41.

14. Baird AJ, Amos GJ, Saad NF, Benson MD. Retrospective audit to determine the diagnostic accuracy of primovist-enhanced MRI in the detection of hepatocellular carcinoma in cirrhosis with explant histopathology correlation. J Med Imaging Radiat Onco. 2013; 57: 314-320.

15. Toso C, Mentha G, Kneteman NM, Majno P. The place of down staging for hepatocellular carcinoma. J Hepatol. 2010; 52: 930-936.